New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable…
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement…